Can colchicine tame heart inflammation? new study aims to find out

NCT ID NCT07064109

Recruiting now Knowledge-focused Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing colchicine, an anti-inflammatory drug, in 380 people who have had a heart attack or unstable angina. Researchers want to understand why some patients respond well and others don't, by looking at their genes, proteins, and other markers. The goal is to build a model that predicts who will benefit most from colchicine therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Colchicine 0.5 mg oral tablet once daily
What this could lead to: If successful, this could help doctors predict which heart attack patients will benefit most from colchicine, personalizing anti-inflammatory treatment.
What could go wrong: This is an observational study, not a randomized trial, so it cannot prove cause and effect. Results may not apply to all patients, and colchicine can cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACS (ACUTE CORONARY SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACS (ACUTE CORONARY SYNDROME)

Contacts and locations

Locations

Shanghai Tongji Hospital
RECRUITING

Shanghai, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.